---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113963"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:41:10.685974+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kezar receives unsolicited $1.10/share acquisition proposal from Concentra Biosciences

## Summary
- Concentra offers $1.10 per share plus a contingent value right for 80% of net proceeds from out-licensing or disposition of Kezar's programs.
- Tang Capital Management, which beneficially owns ~9.9% of Kezar, is Concentra's controlling stockholder.
- Kezar's Board will evaluate the non-binding proposal to determine the best course for stockholders; no immediate action required.

## SEC filing metadata
- accession: 0000950170-24-113963
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/0000950170-24-113963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/kzr-20241010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113963
- JSON: https://secwatch.observer/filing/0000950170-24-113963.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113963.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.